CNCR vs. SPMO

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and SPMO (Invesco S&P 500 Momentum ETF) are both exchange-traded funds - CNCR is a Health & Biotech Equities fund tracking the Loncar Cancer Immunotherapy Index, while SPMO is a Momentum fund tracking the S&P 500 Momentum Index. Both are passively managed. CNCR charges 0.79%/yr vs 0.13%/yr for SPMO.

Performance

CNCR vs. SPMO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Invesco S&P 500 Momentum ETF (SPMO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

SPMO

• 1D: 1.31%
• 1M: 14.80%
• YTD: 29.70%
• 6M: 30.19%
• 1Y: 46.28%
• 3Y*: 42.80%
• 5Y*: 24.51%
• 10Y*: 20.89%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. SPMO - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
SPMO Invesco S&P 500 Momentum ETF	29.14%

CNCR vs. SPMO - Sectors Allocation Comparison

Sectors	CNCR	SPMO
Healthcare	96.6%	6.7%
Financial Services	3.3%	5.9%
Basic Materials	-	1.6%
Communication Services	-	9.2%
Consumer Cyclical	-	1.3%
Consumer Defensive	-	4.3%
Energy	-	3.4%
Industrials	-	11.3%
Real Estate	-	1.0%
Technology	-	52.6%
Utilities	-	2.8%

Return for Risk

CNCR vs. SPMO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPMO

SPMO Risk / Return Rank: 77
SPMO Sharpe Ratio Rank: 80
SPMO Sortino Ratio Rank: 78
SPMO Omega Ratio Rank: 78
SPMO Calmar Ratio Rank: 74
SPMO Martin Ratio Rank: 76

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. SPMO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Invesco S&P 500 Momentum ETF (SPMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	SPMO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.64	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	1.28	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	1.03	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	1.01	—

Drawdowns

CNCR vs. SPMO - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum SPMO drawdown of -30.95%. Use the drawdown chart below to compare losses from any high point for CNCR and SPMO.

Drawdown Indicators

	CNCR	SPMO	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-30.95%	+30.95%
Max Drawdown (1Y) Largest decline over 1 year	—	-12.70%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-20.13%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-22.74%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-30.95%	—
Current Drawdown Current decline from peak	0.00%	0.00%	0.00%
Average Drawdown Average peak-to-trough decline	0.00%	-4.60%	+4.60%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.26%	—

Volatility

Volatility by Period

	CNCR	SPMO	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	7.38%	—
Volatility (6M) Calculated over the trailing 6-month period	—	14.44%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	17.65%	-17.65%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	19.31%	-19.31%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	20.31%	-20.31%

CNCR vs. SPMO - Expense Ratio Comparison

CNCR has a 0.79% expense ratio, which is higher than SPMO's 0.13% expense ratio.

Dividends

CNCR vs. SPMO - Dividend Comparison

CNCR has not paid dividends to shareholders, while SPMO's dividend yield for the trailing twelve months is around 0.66%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SPMO Invesco S&P 500 Momentum ETF	0.66%	0.73%	0.48%	1.63%	1.66%	0.52%	1.27%	1.39%	1.05%	0.77%	1.94%	0.36%

Frequently Asked Questions

Which ETF is better, CNCR or SPMO?

On fees, SPMO is cheaper at 0.13% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or SPMO?

SPMO is cheaper with a 0.13% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, CNCR or SPMO?

SPMO has the higher dividend yield at 0.66%, compared with 0.00% for CNCR.

What is the main difference between CNCR and SPMO?

CNCR is categorized as Health & Biotech Equities, while SPMO is Momentum. CNCR tracks Loncar Cancer Immunotherapy Index, while SPMO tracks S&P 500 Momentum Index. They also come from different issuers: Exchange Traded Concepts and Invesco. Their fees differ too: 0.79% for CNCR and 0.13% for SPMO.